Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Mar 12:100:100743.
doi: 10.1016/j.curtheres.2024.100743. eCollection 2024.

Analysis of a Serious Adverse Reaction of Pulmonary Fibrosis Caused by Dronedarone

Affiliations
Case Reports

Analysis of a Serious Adverse Reaction of Pulmonary Fibrosis Caused by Dronedarone

Yuyan Chen et al. Curr Ther Res Clin Exp. .

Abstract

Objective: This study aims to analyze a severe adverse reaction of pulmonary fibrosis induced by dronedarone hydrochloride tablets, and to provide a reference for clinical rational medication through drug precautions.

Methods: A case of pulmonary fibrosis induced by dronedarone hydrochloride tablets, along with related literature was retrospectively analyzed.

Results: Patients over 65 years old with a history of exposure to amiodarone may increase the incidence of pulmonary toxicity induced by dronedarone, and dronedarone should not be selected as a substitute treatment drug for patients with amiodarone-induced pulmonary toxicity.

Conclusions: It is recommended that clinicians monitor the diffusion capacity of carbon monoxide and lung ventilation function of patients before and after using dronedarone for treatment. For patients with a history of amiodarone exposure, intermittent monitoring of chest X-rays and lung function is necessary. If lung function decreases, dronedarone should be immediately discontinued.

Keywords: Adverse reactions; Amiodarone hydrochloride tablets; Dronedarone hydrochloride tablets; Drug precaution; Pulmonary fibrosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Figure 1
Figure 1
Comparison of the structures of amiodarone and dronedarone.
Figure 2
Figure 2
Comparison of chest CT changes in the patient.
Figure 3
Figure 3
Changes in the course of the patient's illness.

Similar articles

Cited by

References

    1. Budin CE, Cocuz IG, Sabău AH, et al. Pulmonary fibrosis related to amiodarone—is it a standard pathophysiological pattern? A case-based literature review. Diagnostics (Basel) 2022;12(12):3217. - PMC - PubMed
    1. Stack S, Nguyen DV, Casto A, Ahuja N. Diffuse alveolar damage in a patient receiving dronedarone. Chest. 2015;147(4):e131–e133. - PubMed
    1. Hernández Voth AR, Catalán JS, Benavides Mañas PD, et al. A 73-year-old man with interstitial lung disease due to dronedarone. Am J Respir Crit Care Med. 2012;186(2):201–202. - PubMed
    1. Money DB, Lee DH, Hadar A, et al. Amiodarone for the treatment of arrhythmias in COVID-19 patients does not increase the risk of pulmonary fibrosis: a retrospective cohort study. Cureus. 2023;15(1):e34109. - PMC - PubMed
    1. Prescribing information for dronedarone. http://products.sanofi.us/multaq/multaq.html. Accessed September 18, 2013.

Publication types

LinkOut - more resources